A preliminary analysis and model of prostate injection distributions

Prostate

Volumn 66, Issue 4, 2006, Pages 344-357

  Chowning, Scott L ^a   Susil, Robert C ^a   Krieger, Axel ^b   Fichtinger, Gabor ^a,b   Whitcomb, Louis L ^b   Atalar, Ergin ^a,c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Johns Hopkins University   (United States)

^c BILKENT UNIVERSITY   (Turkey)

Author keywords

Drug delivery systems; Injections; Magnetic resonance imaging; Prostate

Indexed keywords

CONTRAST MEDIUM; GADOLINIUM; GADOLINIUM PENTETATE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; DOG; DRUG DELIVERY SYSTEM; HUMAN; HUMAN TISSUE; INJECTION; MALE; MODEL; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSTATE;

ANIMALS; ANTINEOPLASTIC AGENTS; DOGS; FORECASTING; MAGNETIC RESONANCE IMAGING; MALE; MODELS, THEORETICAL; PROSTATE; PROSTATIC NEOPLASMS; RECTUM;

EID: 33644783055     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20298     Document Type: Article

References (26)

1. Livraghi T, Festi D, Monti F, Salmi A, Velotti C. US-guided percutaneous alcohol injection of small hepatic and abdominal tumors. Radiology 1986;161(2):309-312.
2. Fujimoto T. The experimental and clinical studies of percutaneous ethanol injection therapy (PEIT) under ultrasonography for small hepatocellular carcinoma. Acta Hepatolog Jap 1988; 29:52.
3. Solbiati L, Giangrande A, De Pra L, Belloti E, Cantu P, Ravetto C. Percutaneous ethanol injection of parathyroid tumors under US guidance: Treatment for secondary hyperparathyroidism. Radiology 1985;155(3):607-610.
4. Takeda S, Michigishi T, Takazakura E. Successful ultrasonically guided percutaneous ethanol injection for secondary hyperparathyroidism. Nephron 1992;62(1):100-103.
5. Goya N, Ishikawa N, Ito F, Kobayashi C, Tomizawa Y, Toma H. Transurethral ethanol injection therapy for prostatic hyperplasia: 3 year results. J Urol 2004;172(3):1017-1020.
6. Susil RC, Krieger A, Derbyshire JA, Tanacs A, Whitcomb LL, Fichtinger G, Atalar E. System for MR image-guided prostate interventions: Canine study. Radiology 2003;228(3):886-894.
7. Plante MK, Gross AL, Kliment J, Kida M, Zvara P. Intraprostatic ethanol chemoablation via transurethral and transperineal injection. BJU Int 2003;91(1):94-98.
8. Nelson PS. Identifying immunotherapeutic targets for prostate carcinoma through the analysis of gene expression profiles. Ann N Y Acad Sci 2002;975:232-246.
9. DeWeese TL, van der Poel H, Li S, Mikhak B, Drew R, Goemann M, Hamper U, DeJong R, Detorie N, Rodriguez R. A phase I trial of CV706, a replication competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res 2001;61(20):7464-7472.
10. Nemunaitis J. Selective replicating viral vectors: Potential for use in cancer gene therapy. Bio Drugs 2003;17(4):251-262.
11. Mercatante DR, Mohler JL, Kole R. Cellular response to an antisense-mediated shift of Bcl-x pre-mRNA splicing and antineoplastic agents. J Biol Chem 2002;277(51):49374-49382.
12. Trudel S, Trachtenberg J, Toi A, Sweet J, Hua Li Z, Jewett M, Tshilias J, Zhuang LH, Hitt M, Wan Y. A phase I trial of adenovector-mediated delivery of interleukin-2 (AdIL-2) in high-risk localized prostate cancer. Cancer Gene Ther 2003; 10(10):755-763.
13. Li S, Simons J, Detorie N, O'Rourke B, Hamper U, DeWeese TL. Dosimetric and technical considerations for interstitial adenoviral gene therapy as applied to prostate cancer. Int J Radiat Oncol Biol Phys 2003;55(1):204-214.
14. Bhutani MS. Endoscopic ultrasound guided antitumor therapy. Endoscopy 2003;35(8):S54-S56.
15. Dudouet P, Portalez D, Lhez JM, Elman B, Larroque JM, Bachaud JM, Redon A, Ribot JF. Trans-rectal ultrasonography (TRUS) with lipiodol injection for localization of the prostatic apex before radiotherapy planning. Radiother Oncol 2001;61(2):135-141.
16. Rauh G, Pieczek A, Irwin W, Schainfeld R, Isner JM. In vivo analysis of intramuscular gene transfer in human subjects studied by on-line ultrasound imaging. Hum Gene Ther 2001; 12(12):1543-1549.
17. Yu KK, Hricak H. Imaging prostate cancer. Radiol Clin North Am 2000;38(1):59-85,viii.
18. Savoca G, De Stefani S, Gattucio I, Paolinelli D, Stacul F, Belgrano E. Percutaneous ethanol injection of the prostate as minimally invasive treatment for benign prostatic hyperplasia: Preliminary report. Eur Urol 2001;40(5):504-508.
19. Krieger A, Susil RC, Menard C, Coleman JA, Fichtinger G, Atalar E, Whitcomb LL. Design of a novel MRI compatible manipulator for image guided prostate interventions. IEEE Trans Biomed Eng 2005;52(2):306-313.
20. Ditrolio J, Patel P, Watson RA, Irwin RJ. Chemo-ablation of the prostate with dehydrated alcohol for the treatment of prostatic obstruction. J Urol 2002;167(5):2100-2103; discussion 2103-21034.
21. McConnell JD. Benign prostatic hyperplasia: diagnosis and treatment (clinical practice guideline). Rockville, MD: Agency for Health Care Policy and Research, Public Health Service, U.S. Department of Health and Human Services; 1994. Report # AHCPR 94.0582.
22. Zlotta AR, Raviv G, Peny MO, Noel JC, Haot J, Schulman CC. Possible mechanisms of action of transurethral needle ablation of the prostate on benign prostatic hyperplasia symptoms: A neurohistochemical study. J Urol 1997;157(3):894-899.
23. Littrup PJ, Lee F, Borlaza GS, Sacknoff EJ, Torp-Pedersen S, Gray JM. Percutaneous ablation of canine prostate using transrectal ultrasound guidance. Absolute ethanol and Nd:YAG laser. Invest Radiol 1988;23(10):734-739.
24. Alexander AL, Barrette TR, Unger EC. Magnetic resonance guidance of percutaneous ethanol injection in liver. Acad Radiol 1996;3(1):18-25.
25. Walsh PC, editor. Campbell's urology. Philadelphia: W.B. Saunders; 2002.
26. Sato C, Naganawa S, Nakamura T, Kumada H, Miura S, Takizawa O, Ishigaki T. Differentiation of noncancerous tissue and cancer lesions by apparent diffusion coefficient values in transition and peripheral zones of the prostate. J Magn Reson Imaging 2005;21(3):258-262.